Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Swiss stocks - Factors to watch on Sept 22

Published 2016-09-22, 01:11 a/m
© Reuters.  Swiss stocks - Factors to watch on Sept 22

ZURICH, Sept 22 (Reuters) - The following are some of the main factors expected to affect Swiss stocks on Thursday:

SWISS-EU

Legislation giving locals hiring preference, a compromise aimed at preserving Switzerland's economic treaties with the European Union while still easing pressure on the job market from foreign workers, cleared a first hurdle in Swiss parliament on Wednesday.

For more, click on GATE.S

The European Union (EU) regulators have greenlit the acquisition of Swiss Gategroup by Chinese conglomerate HNA Group, the EU said on Wednesday.

For more, click on GATE.S

BANKS

UBS UBSG.S and Credit Suisse CSGN.S are among the banks which have set up offshore accounts for customers in the Bahamas, Swiss newspaper Tages-Anzeiger reported. The two banks have set up around 9,500 companies each in the tax free country over the last 25 years, according to information revealed in a data leak.

COMPANY STATEMENTS CPR-CH

* SGS SGSN.S said it acquired the assets and license of John R. McCrea Agency, Inc. (McCrea), an official designated inspection agency licensed by the US Department of Agriculture. It expects it to generate annual revenues of approximately USD 0.5 million. SGSN.S

* Nestle NESN.S to launch global premium chocolate brands range in India, the Economic Times reported. NESN.S

* Groupe Minoteries SA GMI.S said it had a net profit of 2.3 million Swiss francs in the first half of 2016. GMI.S

* Zueblin Immobilien Holding ZUBN.S said its CFO and COO Thomas Wapp leaves the company at the end of March 2017 in order to join Allreal Group ALLN.S as CFO. The company will inform on his successor in due time. ZUBN.S ALLN.S

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

* Relief Therapeutics RLFB.S reported a first half loss of 4.62 million francs, from a loss 3.48 million francs a year earlier. RLFB.S

* Newron Pharmaceuticals NWRN.S , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, said it has re-submitted the New Drug Application (NDA) for Xadago (safinamide), a treatment for Parkinson's disease, to the US Food and Drug Administration. NWRN.S

* Huber + Suhner HUBN.S said it struck a strategic alliance with Germany's Weidmueller to be able to supply rail industry customers with complete, 100 percent tested solutions for the connection and transmission of power, signals and data. HUBN.S

ECONOMY M-CH

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.